Skip to main content

Table 4 Multivariate Cox proportional hazard model analysis of PFS and OS

From: Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Variable Progression-free survival Overall survival
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Histology       
ADC vs non-ADC 1.154 0.637-2.622 0.255 1.118 0.563-2.527 0.248
Performance status       
0-1 vs 2-3 1.845 1.052-2.995 0.114 2.532 1.219-4.325 0.013
Disease stage       
IIIB vs IV 0.875 0.317-2.152 0.416 1.272 0.428-2.257 0.167
EGFR status       
Wild-type vs mutation 2.726 1.415-4.655 0.011 2.615 1.338-4.524 0.014
MUC1 mRNA at B0       
Positivity vs negativity 2.359 1.155-4.326 0.018 2.494 1.536-4.721 0.015
MUC1 mRNA at B4w       
Positivity vs negativity 2.855 1.512-4.779 0.007 2.842 1.975-5.013 0.009
VEGF mRNA at B0       
Positivity vs negativity 2.453 1.415-4.592 0.013 2.577 1.482-4.683 0.011
VEGF mRNA at B4w       
Positivity vs negativity 3.012 2.103-5.148 0.004 2.910 1.971-5.106 0.006
  1. ADC, adenocarcinoma.